A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
=== Chemical synthesis === The demand for vanilla flavoring has long exceeded the supply of vanilla beans. As of 2001, the annual demand for vanillin was 12,000 tons, but only 1,800 tons of natural vanillin were produced. The remainder was produced by chemical synthesis. Vanillin was first synthesized from eugenol (found in oil of clove) in 1874–75, less than 20 years after it was first identified and isolated. Vanillin was commercially produced from eugenol until the 1920s. Later it was synthesized from lignin-containing "brown liquor", a byproduct of the sulfite process for making wood pulp. Counterintuitively, though it uses waste materials, the lignin process is no longer popular because of environmental concerns, and today most vanillin is produced from guaiacol. Several routes exist for synthesizing vanillin from guaiacol. At present, the most significant of these is the two-step process practiced by Rhodia since the 1970s, in which guaiacol (1) reacts with glyoxylic acid by electrophilic aromatic substitution. The resulting vanillylmandelic acid (2) is then converted by 4-hydroxy-3-methoxyphenylglyoxylic acid (3) to vanillin (4) by oxidative decarboxylation.
==== South Korea ==== South Korea's funeral arrangements have drastically changed in the course of only two decades according to Chang-Won Park. Park states that around the 1980s at home funeral ceremonies were the general norm, straying away from anywhere that was not a family home. Dying close to home, with friends and family, was considered a 'good death', while dying away from home was considered a 'bad death'. This gradually changed as the upper and middle class started holding funerals in the mortuaries of hospitals. This posed an issue for hospitals because of the rapid increase in funerals being held and maxing occupancy. This resolved when a law was passed to allow the civilian population to hold funerals in the mortuaries of hospitals. The lower class then followed suit, copying the newly set traditions of the upper classes. With this change, the practice of cremation became viewed more as an alternative to traditional burials. Cremation was first introduced by Buddhism, but was banned in 1470. It was not until the Japanese colonization period that cremation was reintroduced in 1945 and the ban later lifted. It took until 1998 for cremation to rapidly grow in popularity.
== Management == Prediabetes is a curable disease state, and people can routinely return to normoglycemia (normal glucose metabolism) with interventions. Although some drugs can delay the onset of diabetes, lifestyle modifications play a greater role in the prevention of diabetes. Intensive weight loss and lifestyle intervention, if sustained, may improve glucose tolerance substantially and prevent progression from IGT to type 2 diabetes. The Diabetes Prevention Program (DPP) study found a 16% reduction in diabetes risk for every kilogram of weight loss. Reducing weight by 7% through a low-fat diet and performing 150 minutes of exercise a week is the goal. The ADA guidelines recommend modest weight loss (5–10% body weight), moderate-intensity exercise (30 minutes daily), and smoking cessation. There are many dietary approaches that can reduce the risk of progression to diabetes. Most involve the reduction of added sugars and fats but there remains a lack of conclusive evidence proving the best approach. For patients with severe risk factors, prescription medication may be appropriate. The American Diabetes Association recommends that prescription medications may be considered for those with prediabetes, including those in a specific subgroup who are more likely to have a greater benefit from medications and are at a higher risk of progressing to diabetes. This subgroup of people includes those with a BMI greater than 35, age less than 60, women with a history of gestational diabetes, a fasting plasma glucose greater than 110 or an A1c greater than 6%.
== I == idiopathic – idiopathic thrombocytopenia purpura – IHS – immune complex – immune deficiency/immunodeficiency – immune response – immune system – immune thrombocytopenic purpura – immunity – immunization – immunocompetent – immunocompromised – immunodeficiency – immunogen – immunogenicity – immunoglobulin (Ig) – immunoglobulin A (IgA) – immunoglobulin D (IGD) – immunoglobulin E (IGE) – immunoglobulin G (IGG) – immunoglobulin M (IGM) – immunomodulator – immunostimulant – immunosuppression – immunotherapy – immunotoxin – in vitro – in vivo – incidence – Incubation period – IND – Indian Health Service (IHS) – infection – infectious – informed consent – infusion – inoculation – institutional review board (IRB) – integrase – integrase inhibitors – Interaction – interferon – interleukin-1 (IL-1) – interleukin-2 (IL-2) – interleukin-4 (IL-4) – interleukin-12 (IL-12) – interleukins – International Center for Research on Women – intramuscular (IM) – intravenous – intravenous immunoglobulin (IVIG) – intravitreal – Investigational New Drug (IND) – IRB – ITP – IVIG
Sources: en.wikipedia.org
=== In the West Pacific === Native aluminium has been reported also in cold seeps in the northeastern continental slope of the South China Sea and Chen et al. (2011) have proposed a theory of its origin as resulting by reduction from tetrahydroxoaluminate Al(OH)4− to metallic aluminium by bacteria.
== Further reading == The Folger Way: Coffee Pioneering Since 1850, by Ruth Waldo Newhall (1910–2003), married to Scott Newhall (1914–1992), late of the San Francisco Chronicle, J.A. Folger (publisher) (1961); OCLC 5838971
=== EC 2.6.99: Transferring Other Nitrogenous Groups === EC 2.6.99.1: dATP(dGTP)—DNA purinetransferase EC 2.6.99.2: pyridoxine 5′-phosphate synthase EC 2.6.99.3: O-ureido-L-serine synthase EC 2.6.99.4: Now EC 2.3.1.234, N6-L-threonylcarbamoyladenine synthase.
=== Distance restraints === A crosspeak in a NOESY experiment signifies spatial proximity between the two nuclei in question. Thus each peak can be converted into a maximum distance between the nuclei, usually between 1.8 and 6 angstroms. The intensity of a NOESY peak is proportional to the distance to the minus 6th power, so the distance is determined according to the intensity of the peak. The intensity-distance relationship is not exact, so usually a distance range is used. It is important to assign the NOESY peaks to the correct nuclei based on the chemical shifts. If this task is performed manually, it is usually very labor-intensive since proteins usually have thousands of NOESY peaks. Some computer programs such as PASD/XPLOR-NIH, UNIO, CYANA, ARIA/CNS, and AUDANA/PONDEROSA-C/S in the Integrative NMR platform perform this task automatically on manually pre-processed listings of peak positions and peak volumes, coupled to a structure calculation. Direct access to the raw NOESY data without the cumbersome need of iteratively refined peak lists is so far only granted by the PASD algorithm implemented in XPLOR-NIH, the ATNOS/CANDID approach implemented in the UNIO software package, and the PONDEROSA-C/S and thus indeed guarantees objective and efficient NOESY spectral analysis. To obtain as accurate assignments as possible, it is a great advantage to have access to carbon-13 and nitrogen-15 NOESY experiments, since they help to resolve overlap in the proton dimension. This leads to faster and more reliable assignments, and in turn to better structures.
== Personal life == Zverev lives in Monte Carlo, Monaco. He grew up in Hamburg and also has spent his winters living in Florida at the Saddlebrook Academy. He can speak German, Russian, and English. Zverev has a daughter, Mayla, who was born in 2021 to Brenda Patea, an ex-girlfriend. Both parents reached an out-of-court financial settlement after a lawsuit over alleged physical assault was filed against Zverev by the ex-partner in 2023. Since 2021, Zverev has been dating German actress Sophia Thomalla. In 2017, Zverev said that his tennis idol is Roger Federer. He is a fan of the Miami Heat and Bayern Munich and wore the jersey of Bayern player Michael Olise during the 2026 BMW Open. In his spare time, he enjoys playing basketball and golf. His best friend on the tennis tour is Brazilian doubles specialist Marcelo Melo. He is also close friends with Dominic Thiem and Andrey Rublev, and has known the latter since childhood. Zverev filed a lawsuit against the ACE Group International and its CEO, Patricio Apey, accusing them of "unlawful restraint of trade". He argued that the contract between them was oppressive, but eventually agreed to settle the dispute out of court before the trial began.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.